CBUS

Over the past six months, Cibus, Inc.'s stock (CBUS) has fluctuated, with a 52-week range between $1.09 and $4.19, and was around $1.57-$1.61 in late September 2026, showing an 8.24% decrease in the past month but a 14.71% increase over the last 12 months. Key events include the Q1 2026 earnings report on May 14, 2026, where Cibus reported a net loss of $21.2 million despite raising $37 million through public offerings. On June 8, 2026, Craig Wichner was appointed as the new CEO. Europe recognized nature-based plant improvement on June 17, 2026, which aligns with Cibus's gene-editing approach. The Q2 2026 earnings report on August 13, 2026, revealed a net loss of $22.1 million and revenue of $0.99 million, missing analyst expectations, and the company disclosed a 'going concern risk'. The US launch of the rice herbicide tolerance product was delayed from 2028 to 2029 due to herbicide registration. In September 2026, Wall Street Zen and Weiss Ratings downgraded Cibus's stock from 'hold' to 'sell'.